Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Settings
Settings
Dynamic quotes
OFFON

school135perm Homepage > Equities > Xetra > Evotec AG EVT DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions
Quotes 5-day view Delayed Quote. Delayed Xetra
01/08/2018 01/09/2018 01/10/2018 01/11/2018 01/12/2018 Date
14.5(c) 14.055(c) 13.72(c) 13.95(c) 14.35(c) Last
2 548 970 1 667 355 1 962 091 1 192 155 1 335 110 Volume
+3.72% -3.07% -2.38% +1.68% +2.87% Change
More quotes
Financials (€)
Sales 2017 247 M
EBIT 2017 41,5 M
Net income 2017 25,9 M
Debt 2017 103 M
Yield 2017 -
Sales 2018 329 M
EBIT 2018 68,7 M
Net income 2018 41,4 M
Debt 2018 98,5 M
Yield 2018 -
P/E ratio 2017 75,53
P/E ratio 2018 48,64
EV / Sales2017 8,98x
EV / Sales2018 6,73x
Capitalization 2 117 M
More Financials
Company
Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies.It operates through the EVT Execute and EVT Innovate segments.The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes...
Sector
Biotechnology & Medical Research
Calendar
01/15 | 11:30amPresentation
More about the company
Surperformance© ratings of Evotec AG
Trading Rating : Investor Rating :
More Ratings
Latest news on EVOTEC AG
01/10EVOTEC : Apeiron, Evotec to get 3 mn milestone payment from Sanofi in immuno-onc..
01/08EVOTEC : and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sa..
01/08EVOTEC : And apeiron achieve first milestone in immuno-oncology alliance with sa..
01/05EVOTEC : to attend upcoming investor conferences
01/03EVOTEC : to Attend Upcoming Investor Conferences
01/03EVOTEC : to attend upcoming investor conferences
01/03EVOTEC : To attend upcoming investor conferences
2017EVOTEC AG : Release according to Article 26, Section 1 of the WpHG [the German S..
2017EVOTEC AG : Release according to Article 26, Section 1 of the WpHG [the German S..
2017EVOTEC AG : Release according to Article 26, Section 1 of the WpHG [the German S..
More news
Sector news : Biotechnology & Medical Research - NEC
01/12Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
01/08$11 billion biotech binge fuels forecasts of 2018 M&A surge
01/08SANOFI : and Regeneron boost investment in cancer drug cemiplimab
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
More sector news : Biotechnology & Medical Research - NEC
school135perm Strategies on EVOTEC AG
EVOTEC AG - 2017
A good level to buy
BUY
More Strategies
Latest Tweets
01/08Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with S..
01/08APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with S..
01/08Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with S..
01/08Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with S..
01/08Evotec : and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with..
More tweets
Qtime:57
News from SeekingAlpha
2017Evotec enters into research collaboration with CRTD to discover therapies for..
2017Evotec (EVTCY) Presents At Jefferies 2017 London Healthcare Conference - Slid..
2017Evotec's (EVOTF) CEO Werner Lanthaler on Q3 2017 Results - Earnings Call Tran..
2017MY JOURNEY TO FINANCIAL INDEPENDENCE : 85-Stock October Portfolio Update - Buyin..
2017Evotec AG ADR 2017 Q3 - Results - Earnings Call Slides
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | school135perm
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 17,5 €
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG6.30%2 582
CELLTRION, INC.--.--%36 142
IQVIA HOLDINGS INC2.00%20 770
LONZA GROUP0.38%20 113
INCYTE CORPORATION-1.74%19 639
ALNYLAM PHARMACEUTICALS, INC.0.79%12 591
Copyright © 2018 Surperformance. All rights reserved.